Accession Number:

AD1087498

Title:

Novel Small-Molecule Inhibitor of Tyk2: Lucrative Therapeutic Target in Lupus

Descriptive Note:

Technical Report,01 Sep 2016,28 Feb 2019

Corporate Author:

SRI International Menlo Park United States

Personal Author(s):

Report Date:

2019-06-01

Pagination or Media Count:

11.0

Abstract:

This research project explored the use of small molecule inhibitors of Tyk2 and Jak1 for treating lupus like disease pathology in mouse models of lupus. In our findings we report that 6-week treatment of lupus-proneNZBxNZWF1 mice with small molecule inhibitor of Tyk2Jak1 significantly lowers the pathological auto-antibody production. Similar treatment in MRLlpr model of lupus did not have any effect. The treatment ofNZBxNZWF1 mice also leads to a drop in the number of germinal centers in the spleen as well as a decrease in spleen weights. Since lupus is a chronic disease, we think that a prolonged treatment 6 weeks will show more profound effects on other lupus related disease pathologies like kidney damage. Over all, the treatment has shown potential for significantly improving the disease pathology in NZBxNZWF1 mouse model of lupus.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE